Drug intelligence / Profile preview

AIRISE-COV

Development stage: Preclinical
Lead developer: PDX Pharmaceuticals
Modality: Vaccines & Immunotherapeutics

Overview

AIRISE-COV is a prophylactic vaccine candidate developed by PDX Pharmaceuticals for the prevention of COVID-19. It targets the SARS-CoV-2 antigen, acting as an inhibitor to elicit an immune response against the virus. The drug is intended for use in infectious and respiratory diseases, specifically COVID-19. As of June 2025, it remains in preclinical development and has not entered clinical trials or received regulatory approval[1][2].

Brand names: AIRISE-COV
Other names: AIRISE-COV

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on AIRISE-COV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIRISE-COV.

Explore the full profile